droxicam

01/01/1991 - "A double-blind randomised controlled trial of droxicam versus indomethacin in rheumatoid arthritis."
01/01/1991 - "In conclusion, droxicam (20mg/day) seems to be as effective as indomethacin (100mg/day) in the alleviation of symptoms in patients with rheumatoid arthritis."
01/01/1991 - "The studies which have already been performed in healthy volunteers and in patients with osteoarthritis and rheumatoid arthritis, to evaluate the efficacy and the tolerance of droxicam in patients suffering from such clearly inflammatory processes demonstrate an analgesic potential and anti-inflammatory effects which become noticeable after two weeks of treatment, and the drug is well-tolerated."
01/01/1991 - "This double-blind randomized controlled trial compares the efficacy of droxicam (20mg/day) and that of indomethacin (100mg/day) administered to 20 patients (7 men, 13 women; aged 54.7 +/- 13.2 years) with active classical or definite rheumatoid arthritis during 9 weeks, after a 7-day single-blind run-in paracetamol (1,500mg/day) period. "
01/01/1991 - "Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis."

03/01/1993 - "[Efficacy of and tolerance to a new NSAID in the treatment of arthrosis: droxicam. "
03/01/1993 - "A four-week open study was carried out to evaluate the efficacy and tolerability of droxicam, a new NSAID, in the treatment of painful osteoarthritis (OA). "
01/01/1991 - "The studies which have already been performed in healthy volunteers and in patients with osteoarthritis and rheumatoid arthritis, to evaluate the efficacy and the tolerance of droxicam in patients suffering from such clearly inflammatory processes demonstrate an analgesic potential and anti-inflammatory effects which become noticeable after two weeks of treatment, and the drug is well-tolerated."

03/01/1993 - "The study showed that both drugs are effective in treating OA, with a mild predominance of droxicam in decreasing pain, functional limitation and chronic inability score. "
01/01/1991 - "However, two patients in the droxicam group were withdrawn at week 3 and two days after week 6 because of epigastric pain and nausea, and cutaneous rash, respectively. "
03/01/1993 - "According to the Authors droxicam has shown to be an effective analgesic and anti-inflammatory agent as judged by its efficacy on pain relief and joint mobility in OA."

07/01/1986 - "In a study of protection against diarrhea induced by castor oil in rats, droxicam and piroxicam showed equal activity (ED50 = 0.081 and 0.079 mg/kg, p.o., respectively) and were 3.9 and 15.6 times more active than isoxicam and phenylbutazone, respectively. "

07/01/1986 - "In U.V. light-induced erythema in guinea pigs, droxicam (ED50, p.o., 1, 2, 3, 4 h: 0.51, 0.94, 1.56, 4.88 mg/kg) was 5-9 times more active than phenylbutazone. "
01/01/1988 - "In Studies of anti-inflammatory activity, droxicam has shown itself to be as active as piroxicam and much more active than phenylbutazone, isoxicam and suprofen, both in acute studies such as carrageenin oedema, nystatin oedema and ultraviolet erythema, and in longer-term tests such as that of the cotton pellet. "